Credit Suisse analyst Vamil Divan raised his price target for Portola Pharmaceuticals to $70 from $58 after the company reported Q2 financial results and provided an update on Bevyxxa and AndexXa. The analyst also notes that the company is working through some manufacturing process modifications for Bevyxxa that could potentially push the U.S. launch of the product to Q1 of 2018, although its base case is still a launch in September-November of 2017. Divan reiterates a Neutral rating on the shares given the current valuation of the stock following the big move it has had both upon Bevyxxa's approval and in the weeks since then.